Tirzepatide (mounjaro) dosed at 20mg per vial and tested by HPLC with a reputable 3rd party.

   Tirzepatide (mounjaro) dosed at 20mg per vial and tested by HPLC and with a reputable 3rd party, Janoshik. We have found 99%+ purity and are using 3rd party Janoshik for testing.

    Tirzepatide is a double receptor agonist that targets the receptors of GIP and GLP-1. By combining the effects of native GIP and GLP-1 with glucagon receptor activation, it exerts a broad appetite-suppressing and metabolic impact. Tirzepatide targets multiple receptors in the body, including GLP-1 and GIP whereas semaglutide only targets the GLP-1 receptor. This broader targeting allows Tirzepatide to potentially offer greater weight loss and metabolic benefits than semaglutide.

 DISCLAIMER: ALL PEPTIDES ARE SOLD FOR REASEARCH PURPOSE ONLY AND HAVE TO BE SOLD NOT FOR HUMAN CONSUMPTION.